AGT and cardiomyopathy: The renin-angiotensin system (RAS) plays an important role in the pathophysiology of doxorubicin-induced cardiomyopathy, and the inhibition of ACE/AngII/AngII type 1 (AT1) receptor (AT1R) axis has been shown to improve doxorubicin-induced cardiomyopathy [8, 10, 11].